|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung JJ, Lau JY, Goh KL and Leung WK: Asia
Pacific Working Group on Colorectal Cancer: Increasing incidence of
colorectal cancer in Asia: Implications for screening. Lancet
Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Temraz S, Mukherji D, Alameddine R and
Shamseddine A: Methods of overcoming treatment resistance in
colorectal cancer. Crit Rev Oncol Hematol. 89:217–230. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scartozzi M, Maccaroni E, Giampieri R,
Pistelli M, Bittoni A, Del Prete M, Berardi R and Cascinu S:
5-Fluorouracil pharmacogenomics: Still rocking after all these
years? Pharmacogenomics. 12:251–265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vigneri PG, Tirrò E, Pennisi MS, Massimino
M, Stella S, Romano C and Manzella L: The insulin/IGF system in
colorectal cancer development and resistance to therapy. Front
Oncol. 5:2302015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weber MM, Fottner C, Liu SB, Jung MC,
Engelhardt D and Baretton GB: Overexpression of the insulin-like
growth factor I receptor in human colon carcinomas. Cancer.
95:2086–2095. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sekharam M, Zhao H, Sun M, Fang Q, Zhang
Q, Yuan Z, Dan HC, Boulware D, Cheng JQ and Coppola D: Insulin-like
growth factor 1 receptor enhances invasion and induces resistance
to apoptosis of colon cancer cells through the Akt/Bcl-x(L)
pathway. Cancer Res. 63:7708–7716. 2003.PubMed/NCBI
|
|
9
|
Alberobello AT, D'Esposito V, Marasco D,
Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C,
et al: Selective disruption of insulin-like growth factor-1 (IGF-1)
signaling via phosphoinositide-dependent kinase-1 prevents the
protective effect of IGF-1 on human cancer cell death. J Biol Chem.
285:6563–6572. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu
K, Yu J and Sung JJ: MicroRNA in colorectal cancer: From benchtop
to bedside. Carcinogenesis. 32:247–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amirkhah R, Farazmand A, Irfan-Maqsood M,
Wolkenhauer O and Schmitz U: The role of microRNAs in the
resistance to colorectal cancer treatments. Cell Mol Biol
(Noisy-le-grand). 61:17–23. 2015.PubMed/NCBI
|
|
12
|
Karaayvaz M, Zhai H and Ju J: miR-129
promotes apoptosis and enhances chemosensitivity to 5-fluorouracil
in colorectal cancer. Cell Death Dis. 4:e6592013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Zheng L, Huang J, Gao F, Lin X,
He L, Li D, Li Z, Ding Y and Chen L: MiR-124 radiosensitizes human
colorectal cancer cells by targeting PRRX1. PLoS One. 9:e939172014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R,
Hu X, Ye X, Lu J, Fan F, Xia L, et al: miR-203 induces oxaliplatin
resistance in colorectal cancer cells by negatively regulating ATM
kinase. Mol Oncol. 8:83–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suto T, Yokobori T, Yajima R, Morita H,
Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T and Kuwano H:
MicroRNA-7 expression in colorectal cancer is associated with poor
prognosis and regulates cetuximab sensitivity via EGFR regulation.
Carcinogenesis. 36:338–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suh MR, Lee Y, Kim JY, Kim SK, Moon SH,
Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, et al: Human embryonic
stem cells express a unique set of microRNAs. Dev Biol.
270:488–498. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Baskerville S, Shenoy A, Babiarz
JE, Baehner L and Blelloch R: Embryonic stem cell-specific
microRNAs regulate the G1-S transition and promote rapid
proliferation. Nat Genet. 40:1478–1483. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin SL, Chang DC, Ying SY, Leu D and Wu
DT: MicroRNA miR-302 inhibits the tumorigenecity of human
pluripotent stem cells by coordinate suppression of the CDK2 and
CDK4/6 cell cycle pathways. Cancer Res. 70:9473–9482. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang GM, Bao CY, Wan FN, Cao DL, Qin XJ,
Zhang HL, Zhu Y, Dai B, Shi GH and Ye DW: MicroRNA-302a suppresses
tumor cell proliferation by inhibiting AKT in prostate cancer. PLoS
One. 10:e01244102015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu L, Lian J, Zhang H, Tian H, Liang M,
Yin M and Sun F: MicroRNA-302a sensitizes testicular embryonal
carcinoma cells to cisplatin-induced cell death. J Cell Physiol.
228:2294–2304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hou N, Torii S, Saito N, Hosaka M and
Takeuchi T: Reactive oxygen species-mediated pancreatic β-cell
death is regulated by interactions between stress-activated protein
kinases, p38 and c-Jun N-terminal kinase, and mitogen-activated
protein kinase phosphatases. Endocrinology. 149:1654–1665. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou N, Han J, Li J, Liu Y, Qin Y, Ni L,
Song T and Huang C: MicroRNA profiling in human colon cancer cells
during 5-fluorouracil-induced autophagy. PLoS One. 9:e1147792014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li B, Li J, Xu WW, Guan XY, Qin YR, Zhang
LY, Law S, Tsao SW and Cheung AL: Suppression of esophageal tumor
growth and chemoresistance by directly targeting the PI3K/AKT
pathway. Oncotarget. 5:11576–11587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Hou N, Faried A, Tsutsumi S,
Takeuchi T and Kuwano H: Inhibition of autophagy by 3-MA enhances
the effect of 5-FU-induced apoptosis in colon cancer cells. Ann
Surg Oncol. 16:761–771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Hou N, Faried A, Tsutsumi S and
Kuwano H: Inhibition of autophagy augments 5-fluorouracil
chemotherapy in human colon cancer in vitro and in vivo model. Eur
J Cancer. 46:1900–1909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vinod BS, Antony J, Nair HH,
Puliyappadamba VT, Saikia M, Narayanan SS, Bevin A and Anto RJ:
Mechanistic evaluation of the signaling events regulating
curcumin-mediated chemosensitization of breast cancer cells to
5-fluorouracil. Cell Death Dis. 4:e5052013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong KL, Kwong DL, Chan TH, Law SY, Chen
L, Li Y, Qin YR and Guan XY: MicroRNA-375 inhibits tumour growth
and metastasis in oesophageal squamous cell carcinoma through
repressing insulin-like growth factor 1 receptor. Gut. 61:33–42.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang L, Liu X, Chen Z, Jin Y, Heidbreder
CE, Kolokythas A, Wang A, Dai Y and Zhou X: MicroRNA-7 targets
IGF1R (insulin-like growth factor 1 receptor) in tongue squamous
cell carcinoma cells. Biochem J. 432:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshioka A, Miyata H, Doki Y, Yasuda T,
Yamasaki M, Motoori M, Okada K, Matsuyama J, Makari Y, Sohma I, et
al: The activation of Akt during preoperative chemotherapy for
esophageal cancer correlates with poor prognosis. Oncol Rep.
19:1099–1107. 2008.PubMed/NCBI
|
|
32
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Faried LS, Faried A, Kanuma T, Aoki H,
Sano T, Nakazato T, Tamura T, Kuwano H and Minegishi T: Expression
of an activated mammalian target of rapamycin in adenocarcinoma of
the cervix: A potential biomarker and molecular target therapy. Mol
Carcinog. 47:446–457. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Faried LS, Faried A, Kanuma T, Nakazato T,
Tamura T, Kuwano H and Minegishi T: Inhibition of the mammalian
target of rapamycin (mTOR) by rapamycin increases chemosensitivity
of CaSki cells to paclitaxel. Eur J Cancer. 42:934–947. 2006.
View Article : Google Scholar : PubMed/NCBI
|
